There are theoretical benefits of delivering drug aerosols to patients with asthma and COPD using Heliox as a carrier gas. The objective of this study was to develop systems to allow bronchodilators nebulised by a breath enhanced jet nebuliser and a vibrating mesh nebuliser to be delivered to patients in Heliox. This was achieved by attaching a reservoir to the nebulisers to ensure inhaled Heliox was not diluted by entrained air. For the vibrating mesh nebuliser, the total output was significantly higher after 5min nebulisation when Heliox rather than air was used as the delivery gas (p<0.001). The proportion of drug in particles <5µm was 58.1% for Heliox and 50.1% when air was entrained. When the breath enhanced nebuliser was used a much higher driving flow of Heliox, compared to air, was required to deliver a similar dose of drug (p<0.05). The total amount of drug likely to be inhaled was significantly higher when the vibrating mesh nebuliser (Aerogen) was used compared to the breath enhanced jet nebuliser (Pari LC plus) (p<0.001). The amount of drug likely to be inhaled was also significantly greater for the adult as opposed to paediatric breathing pattern for all nebulisers and flows tested with the exception of the Aeroneb and Heliox entrainment.In this case, total amounts were similar for both patterns but for the paediatric pattern, the time taken to reach this output was longer. Such information is required to allow appropriate interpretation of clinical trials of drug delivery using Heliox.3